<DOC>
	<DOC>NCT01617629</DOC>
	<brief_summary>The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease progression.</brief_summary>
	<brief_title>Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female patients ≥ 18 years old with histologically confirmed Stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube cancer who were enrolled in CAN003 Able and willing to undergo MNC collection (if required for patients who do not have available Cvac doses) Were enrolled in CAN003 and met protocol criteria for progressive disease Wish to remain in the study and, in the investigator's judgment, the potential benefit of Cvac treatment outweighs the risk Must be nonpregnant and, if of childbearing potential, must use adequate birth control (hormonal or barrier method of birth control or abstinence) for the duration of the study and for 3 months after study completion Able to provide written informed consent White blood cell count (WBC) ≥ 3.0 K/μL, absolute neutrophil count ≥ 1.5 K/μL, hemoglobin ≥ 9.0 g/dL, and platelets ≥100,000/mm3 Pregnant or breastfeeding Other medical conditions which preclude study participation, in the opinion of the investigator Receiving treatment with any other investigational product</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cvac</keyword>
</DOC>